Aldebaran Capital’s AN2 Therapeutics ANTX Stock Holding History

Aldebaran Capital’s Portfolio ANTX Stock Details ANTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-406,623	Closed	-$553K	–	35
2025 Q1	$553K	Buy	406,623 +62,939	+18%	+$79.2K	0.52%	27
2024 Q4	$474K	Buy	343,684 +243,184	+242%	+$295K	0.45%	29
2024 Q3	$108K	Buy	+100,500	New	+$174K	0.1%	37

Other funds holding ANTX

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

LCM

Landscape Capital Management Englewood, New Jersey $1.58B AUM 26.88% 1-Year Est. Return

Bank of Nova Scotia Toronto, Ontario, Canada $57.2B AUM 35.3% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Aldebaran Capital's ANTX Position: Q2 2025 in Review

Aldebaran Capital sold out of AN2 Therapeutics (ANTX) in Q2 2025, closing a stake of 406,623 shares — an estimated $553K sold.

Aldebaran Capital first reported a position in ANTX in Q3 2024 and held it in 3 quarters. The position peaked at $553K in Q1 2025. 36 funds tracked by Wall St. Rank hold ANTX as of Q2 2025.

Aldebaran Capital reported no remaining AN2 Therapeutics position as of Q2 2025 after selling out during the quarter.
Aldebaran Capital sold 406,623 AN2 Therapeutics shares in Q2 2025, an estimated $553K.
Aldebaran Capital first reported a position in AN2 Therapeutics in Q3 2024 and held it in 3 quarters.
Aldebaran Capital's AN2 Therapeutics position peaked at $553K in Q1 2025.
36 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2025.

Based on Aldebaran Capital's 13F filing for Q2 2025, filed 12 Aug 2025.